---
document_datetime: 2025-11-13 09:25:08
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/dasatinib-accord-healthcare-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: dasatinib-accord-healthcare-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6361252
conversion_datetime: 2025-12-30 20:02:11.804513
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Dasatinib Accord Healthcare

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Application number                       | Scope                                                                                                                                                                                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB / EMA/VR/0000306994    | C.I.11.z - to update the RMP for Dasatinib Accord Healthcare in line with European Public Assessment Report (EPAR) for RMP of reference product Sprycel (Dasatinib) (version 18.2, dated 29-Apr-2024) published on the EMA website on 18 June 2025.                                                                                                                                                  | 12/11/2025                          | N/A                                         |                                  |           |
| Variation type IA_IN / EMA/VR/0000288694 | This was an application for a group of variations. B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1 Change within the range of the currently approved pack sizes - Accepted B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1 Change within the range of the currently approved pack sizes - Accepted | 19/08/2025                          |                                             | SmPC, Labelling and PL           |           |

<div style=\"page-break-after: always\"></div>

| B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1 Change within the range of the currently approved pack sizes - Accepted B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1 Change within the range of the currently approved pack sizes - Accepted B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1 Change within the range of the currently approved pack sizes - Accepted B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1 Change within the range of the currently approved pack sizes - Accepted   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|